RecruitingPhase 3NCT04216186
Role of Coenzyme Q in ADHD in Children
Role of Coenzyme Q in Treatment of Attention Deficit Hyperactivity Disorder in Children
Sponsor
Sherief Abd-Elsalam
Enrollment
40 participants
Start Date
Nov 1, 2018
Study Type
INTERVENTIONAL
Conditions
Summary
Role of Coenzyme Q in ADHD in Children
Eligibility
Min Age: 2 YearsMax Age: 18 Years
Plain Language Summary
Simplified for easier understanding
This clinical trial is studying a drug called Atomoxetine and a drug called Coenzyme Q for people with adhd. The study is currently recruiting participants at 1 location. People eligible for this study include aged 2 Years to 18 Years.
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
DRUGAtomoxetine
Atomoxetine once daily
DRUGCoenzyme Q
Coenzyme Q once daily
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT04216186
Related Trials
Fidgeting and Attentional and Emotional Regulation in ADHD
NCT045266001 location
Forward Treatment of Attention Deficit and Hyperactivity Using Solriamfetol (FOCUS-2)
NCT077178799 locations
Forward Treatment of Attention Deficit and Hyperactivity Using Solriamfetol (FOCUS-3)
NCT077178929 locations
Evaluating the Efficacy of Central Executive Training (CET) For Young Children With ADHD
NCT07784348
Impact of Short and Mistimed Sleep on Adolescents With ADHD: The Adolescent Attention and Circadian Timing Study
NCT07684417